MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy

Abstract T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological disease in which multiple genetic abnormalities cooperate in the malignant transformation of T-lymphoid progenitors. Although in pediatric T-ALL, CDKN1B deletions occur in about 12% of the cases and represent one of the most frequent copy number alterations, neither their association with other genetic alterations nor the clinical characteristics of these patients have been determined yet. In this study, we show that loss of CDKN1B increased the prevalence of cell cycle regulator defects in immature T-ALL, usually only ascribed to CDKN2A/B deletions, and that CDKN1B deletions frequently coincide with expression of MEF2C, considered as one of the driving oncogenes in immature early T-cell precursor (ETP) ALL. However, MEF2C-dysregulation was only partially associated with the immunophenotypic characteristics used to define ETP-ALL. Furthermore, MEF2C expression levels were significantly associated with or may even be predictive of the response to glucocorticoid treatment.

[1]  G. Berx,et al.  Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia , 2017, Leukemia.

[2]  A. Ferrando,et al.  The genetics and mechanisms of T cell acute lymphoblastic leukaemia , 2016, Nature Reviews Cancer.

[3]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[4]  S. Strehl,et al.  Complexity of NOTCH1 juxtamembrane insertion mutations in T-cell acute lymphoblastic leukemia , 2016, Leukemia & lymphoma.

[5]  M. Valsecchi,et al.  Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. , 2016, The Lancet. Haematology.

[6]  M. Loh,et al.  The Genomic Landscape of Childhood T-Lineage Acute Lymphoblastic Leukemia , 2015 .

[7]  F. Speleman,et al.  Novel biological insights in T-cell acute lymphoblastic leukemia. , 2015, Experimental hematology.

[8]  T. Imamura,et al.  BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression? , 2015, PloS one.

[9]  F. Speleman,et al.  ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. , 2014, Blood.

[10]  S. Chiaretti,et al.  Genetic profile of T-cell acute lymphoblastic leukemias with MYC translocations. , 2014, Blood.

[11]  R. Wade,et al.  Outcome for children and young people with Early T‐cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003 , 2014, British journal of haematology.

[12]  A. Look,et al.  Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors , 2014, Haematologica.

[13]  A. Ferrando,et al.  Early T-cell precursor acute lymphoblastic leukaemia , 2013, Current opinion in hematology.

[14]  Carsten Denkert,et al.  Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization , 2012, PloS one.

[15]  A. Ferrando,et al.  The molecular basis of T cell acute lymphoblastic leukemia. , 2012, The Journal of clinical investigation.

[16]  B. Meissner,et al.  Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia , 2012, Haematologica.

[17]  J. Meijerink,et al.  NKL homeobox genes in leukemia , 2012, Leukemia.

[18]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[19]  A. Ferrando,et al.  ETV6 mutations in early immature human T cell leukemias , 2011, The Journal of experimental medicine.

[20]  M. Muckenthaler,et al.  Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias , 2011, The Journal of experimental medicine.

[21]  Andrew P. Stubbs,et al.  Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. , 2011, Cancer cell.

[22]  J. Harbott,et al.  Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000 , 2010, Leukemia.

[23]  O. Haas,et al.  Prognostic relevance of TLX3 (HOX11L2) expression in childhood T‐cell acute lymphoblastic leukaemia treated with Berlin–Frankfurt–Münster (BFM) protocols containing early and late re‐intensification elements , 2010, British journal of haematology.

[24]  M. Muckenthaler,et al.  High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. , 2009, Blood.

[25]  V. Beneš,et al.  The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. , 2009, Clinical chemistry.

[26]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[27]  Cheng Cheng,et al.  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. , 2009, The Lancet. Oncology.

[28]  R. Pieters,et al.  Molecular‐genetic insights in paediatric T‐cell acute lymphoblastic leukaemia , 2008, British journal of haematology.

[29]  H. Drexler,et al.  MEF2C is activated by multiple mechanisms in a subset of T-acute lymphoblastic leukemia cell lines , 2008, Leukemia.

[30]  A. Vincent-Salomon,et al.  Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia. , 2008, Blood.

[31]  M. König,et al.  ETV6-NCOA2: A Novel Fusion Gene in Acute Leukemia Associated with Coexpression of T-Lymphoid and Myeloid Markers and Frequent NOTCH1 Mutations , 2008, Clinical Cancer Research.

[32]  Andrew P. Stubbs,et al.  The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. , 2007, Blood.

[33]  Christian Urban,et al.  Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. , 2007, Blood.

[34]  Christopher B. Miller,et al.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.

[35]  Charles Lee,et al.  The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. , 2006, Blood.

[36]  V. Kalscheuer,et al.  Impact of low copy repeats on the generation of balanced and unbalanced chromosomal aberrations in mental retardation , 2006, Cytogenetic and Genome Research.

[37]  A. Hagemeijer,et al.  Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast , 2006, Leukemia.

[38]  E. Macintyre,et al.  CALM-AF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes , 2005, Leukemia.

[39]  F. Sigaux,et al.  HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). , 2005, Blood.

[40]  Wei Chen,et al.  CGHPRO – A comprehensive data analysis tool for array CGH , 2005, BMC Bioinformatics.

[41]  H. Drexler,et al.  The cardiac homeobox gene NKX2-5 is deregulated by juxtaposition with BCL11B in pediatric T-ALL cell lines via a novel t(5;14)(q35.1;q32.2). , 2003, Cancer research.

[42]  E. Lander,et al.  Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. , 2002, Cancer cell.

[43]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[44]  A Orfao,et al.  Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.

[45]  A. Ferrando,et al.  Recent advances on NOTCH signaling in T-ALL. , 2012, Current topics in microbiology and immunology.

[46]  R. Arceci.  The genetic basis of early T–cell precursor acute lymphoblastic leukaemia , 2012 .

[47]  F. Sigaux,et al.  Recurrent molecular deletion of the 12p13 region, centromeric to ETV6/TEL, in T-cell prolymphocytic leukemia. , 2000, The hematology journal : the official journal of the European Haematology Association.

[48]  J. Rowley,et al.  Molecular analysis of the t(8;14)(q24;q11) chromosomal breakpoint junctions in the T-cell leukemia line MOLT-16. , 1997, Genes, chromosomes & cancer.

[49]  G. Paolucci,et al.  [Treatment of acute lymphoblastic leukemia]. , 1971, Minerva pediatrica.